Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.

Neuroplasticity in the mesolimbic dopaminergic system is critical for behavioral adaptations associated with opioid reward and addiction. These processes may be influenced by cholinergic transmission arising from the laterodorsal tegmental nucleus (LDTg), a main source of acetylcholine to mesolimbic...

Full description

Bibliographic Details
Main Authors: Dusica Bajic, Mariano Soiza-Reilly, Allegra L Spalding, Charles B Berde, Kathryn G Commons
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4315441?pdf=render
id doaj-1a900c7de4e54310bc7d4f53f3aa7695
record_format Article
spelling doaj-1a900c7de4e54310bc7d4f53f3aa76952020-11-25T01:28:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01102e011760110.1371/journal.pone.0117601Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.Dusica BajicMariano Soiza-ReillyAllegra L SpaldingCharles B BerdeKathryn G CommonsNeuroplasticity in the mesolimbic dopaminergic system is critical for behavioral adaptations associated with opioid reward and addiction. These processes may be influenced by cholinergic transmission arising from the laterodorsal tegmental nucleus (LDTg), a main source of acetylcholine to mesolimbic dopaminergic neurons. To examine this possibility we asked if chronic systemic morphine administration affects expression of genes in ventral and ventrolateral periaqueductal gray at the level of the LDTg using rtPCR. Specifically, we examined gene expression changes in the area of interest using Neurotransmitters and Receptors PCR array between chronic morphine and saline control groups. Analysis suggested that chronic morphine administration led to changes in expression of genes associated, in part, with cholinergic neurotransmission. Furthermore, using a quantitative immunofluorescent technique, we found that chronic morphine treatment produced a significant increase in immunolabeling of the cholinergic marker (vesicular acetylcholine transporter) in neurons of the LDTg. Finally, systemic administration of the nonselective and noncompetitive neuronal nicotinic antagonist mecamylamine (0.5 or 2 mg/kg) dose-dependently blocked the expression, and to a lesser extent the development, of locomotor sensitization. The same treatment had no effect on acute morphine antinociception, antinociceptive tolerance or dependence to chronic morphine. Taken together, the results suggest that endogenous nicotinic cholinergic neurotransmission selectively contributes to behavioral sensitization to morphine and this process may, in part, involve cholinergic neurons within the LDTg.http://europepmc.org/articles/PMC4315441?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Dusica Bajic
Mariano Soiza-Reilly
Allegra L Spalding
Charles B Berde
Kathryn G Commons
spellingShingle Dusica Bajic
Mariano Soiza-Reilly
Allegra L Spalding
Charles B Berde
Kathryn G Commons
Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.
PLoS ONE
author_facet Dusica Bajic
Mariano Soiza-Reilly
Allegra L Spalding
Charles B Berde
Kathryn G Commons
author_sort Dusica Bajic
title Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.
title_short Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.
title_full Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.
title_fullStr Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.
title_full_unstemmed Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.
title_sort endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Neuroplasticity in the mesolimbic dopaminergic system is critical for behavioral adaptations associated with opioid reward and addiction. These processes may be influenced by cholinergic transmission arising from the laterodorsal tegmental nucleus (LDTg), a main source of acetylcholine to mesolimbic dopaminergic neurons. To examine this possibility we asked if chronic systemic morphine administration affects expression of genes in ventral and ventrolateral periaqueductal gray at the level of the LDTg using rtPCR. Specifically, we examined gene expression changes in the area of interest using Neurotransmitters and Receptors PCR array between chronic morphine and saline control groups. Analysis suggested that chronic morphine administration led to changes in expression of genes associated, in part, with cholinergic neurotransmission. Furthermore, using a quantitative immunofluorescent technique, we found that chronic morphine treatment produced a significant increase in immunolabeling of the cholinergic marker (vesicular acetylcholine transporter) in neurons of the LDTg. Finally, systemic administration of the nonselective and noncompetitive neuronal nicotinic antagonist mecamylamine (0.5 or 2 mg/kg) dose-dependently blocked the expression, and to a lesser extent the development, of locomotor sensitization. The same treatment had no effect on acute morphine antinociception, antinociceptive tolerance or dependence to chronic morphine. Taken together, the results suggest that endogenous nicotinic cholinergic neurotransmission selectively contributes to behavioral sensitization to morphine and this process may, in part, involve cholinergic neurons within the LDTg.
url http://europepmc.org/articles/PMC4315441?pdf=render
work_keys_str_mv AT dusicabajic endogenouscholinergicneurotransmissioncontributestobehavioralsensitizationtomorphine
AT marianosoizareilly endogenouscholinergicneurotransmissioncontributestobehavioralsensitizationtomorphine
AT allegralspalding endogenouscholinergicneurotransmissioncontributestobehavioralsensitizationtomorphine
AT charlesbberde endogenouscholinergicneurotransmissioncontributestobehavioralsensitizationtomorphine
AT kathryngcommons endogenouscholinergicneurotransmissioncontributestobehavioralsensitizationtomorphine
_version_ 1725102442229530624